– Regulatory Submissions Filed and Authorization of Treatment Centers is Underway –

Santa Monica, CA. – August 31, 2022 – Kite, a Gilead Company (Nasdaq: GILD), today announced that it is expanding its business with the launch of operations in Brazil, Singapore and Saudi Arabia. Kite has submitted regulatory applications for its CAR T-cell therapy products in all three countries.

Advanced blood cancers represent an area of significant need across all three countries. In both Singapore and Saudi Arabia, lymphomas are the fifth most common cancer overall; more than 1,000 new cases of non-Hodgkin lymphoma (NHL) are diagnosed in Singapore and nearly 1,700 in Saudi Arabia each year. In Brazil, more than 12,000 cases of NHL are estimated to be diagnosed per year.

“As the global cell therapy leader, Kite is working to bring access to CAR T-cell therapy to new areas around the world where patients currently do not have access to this potential cure for some advanced blood cancers,” said Christi Shaw, Chief Executive Officer of Kite. “We are pleased to continue expanding our international operations and look forward to partnering with the health care systems in these regions.”

Kite teams are now in place working to qualify leading hospitals to administer CAR T-cell therapy in each of the new countries, pending local regulatory approvals, and the Company plans to increase its workforce in these countries in 2022. Kite currently has more than 300 qualified treatment centers globally, including in the U.S., Australia, Canada and Europe, as well as through our joint venture in China and our licensing partner in Japan. 

Kite is the only company dedicated exclusively to the research, development, commercialization and manufacturing of cell therapy on a global scale. Kite is unique in that all functions dedicated to cell therapy are vertically integrated under one leadership team for efficient delivery of the highly specialized and complex end-to-end processes needed to support CAR T-cell therapy.

About Kite
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, with manufacturing operations in North America and Europe. Kite’s singular focus is cell therapy to treat and potentially cure cancer. As the cell therapy leader, Kite has more approved CAR T indications to help more patients than any other company. For more information on Kite, please visit

About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including uncertainties relating to regulatory applications and related filing and approval timelines, including the risk that global health authorities may not approve Kite’s CAR T-cell therapy in the anticipated timelines or at all, and that any regulatory approvals, if granted, may have significant limitations on its use; difficulties or unanticipated expenses in connection with the expansion of Kite’s business into Brazil, Saudi Arabia and Singapore, including its ability to qualify leading hospitals to administer CAR T-cell therapy and to expand workforce in these countries; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Kite and Gilead, and Kite and Gilead assume no obligation and disclaim any intent to update any such forward-looking statements.

Kite, the Kite logo and GILEAD are trademarks of Gilead Sciences, Inc. or its related companies.

For more information on Kite, please visit the company’s website at Follow Kite on social media on Twitter (@KitePharma) and LinkedIn